References
- Gunawardena H, Betteridge ZE, McHugh NE. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology. 2009;48(6): 607–612.
- Sato, S. Clinical and immunological associations of autoantibodies to the 140kDa polypeptide (the US autoantigen) in patients with clinically amyopathic dermatomyositis. Arthritis and Rheumatology. 2003;48(9): 102.
- Damoiseaux J, Vulsteke J, Tseng C, Platteel ACM, Piette Y, Shovman O, et al. Autoantibodies in idiopathic inflammatory myopathies : clinical associations and laboratory evaluation by mono- and multispecific immunoassays. Autoimmunity Reviews. 2019;18(3): 293–305. doi:10.1016/j.autrev.2018.10.004.
- Bohan A, Peter JB. Polymyositis and dermatomyositis. The New England Journal of Medicine. 1975;292: 344–347.
- Borges IBP, Silva MG, Shinjo SK. Prevalence and reactivity of anti-melanoma differentiation-associated gene 5 (anti-MDA-5) autoantibody in Brazilian patients with dermatomyositis*. Anais Brasileiros de Dermatologia. 2018;93(4): 517–523.
- Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. Journal of the American Academy of Dermatology. 2011;65(1): 25–34. doi:10.1016/j.jaad.2010.09.016.
- Kurtzman DJB, Vleugels RA. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features. Journal of the American Academy of Dermatology. 2018;78(4): 776–785. doi:10.1016/j.jaad.2017.12.010.
- Girard C, Vincent T, Bessis D. Dermatomyosite et pneumopathie interstitielle rapidement évolutive associées aux auto- anticorps anti-MDA-5 : une présentation clinique atypique. Annales de Dermatologie et de Vénéréologie. 2013;140(10): 628–634. doi:10.1016/j.annder.2013.04.083.
- Chen Z, Cao M, Plana MN, Liang J, Cai H, Kuwana M, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care and Research (Hoboken). 2013;65(8): 1316–1324.
- Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford). 2012;51(7): 1278–1284.
- Cao H, Pan M, Kang Y, Xia Q, Li X, Zhao X, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care and Research (Hoboken). 2012;64(10): 1602–1610.
- Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010;49(3): 433–440.
- Hall JC, Casciola-Rosen L, Samedy LA, Werner J, Owoyemi K, Danoff SK, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care and Research (Hoboken). 2013;65(8): 1307–1315.
- Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Tincani A, Selmi C, et al. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clinical and Experimental Rheumatology. 2014;32(6): 891–897.
- Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care and Research (Hoboken). 2016;68(5): 689–694.
- Gil B, Merav L, Pnina L, Chagai G. Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review. Clinical Rheumatology. 2016;35: 2125–2130.
- Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis and Rheumatism. 2009;60: 2193–2200.
- Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respiratory Medicine. 2011;105(9): 1380–1387. doi:10.1016/j. rmed.2011.05.006.
- Gerfaud-valentin M, Ahmad K, Piegay F, Fabien N, Raphanel B, Cordier JF, et al. Pneumopathie infiltrante diffuse associée à une dermatomyosite amyopathique avec auto-anticorps anti-MDA5. Revue des Maladies Respiratoires. 2014;31(9): 849–853. doi:10.1016/j.rmr.2014.02.010.
- Ma X, Chen Z, Hu W, Guo Z, Wang Y, Kuwana M, et al. Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum. Clinical Rheumatology. 2016;35(2): 489–493.
- Waldman R, DeWane ME, Lu J. Dermatomyositis part 2: diagnosis and treatment. Journal of the American Academy of Dermatology. 2019;82(2): 283–296.
- Yamaguchi K, Yamaguchi A, Onuki Y, Itai M, Kashiwagi C, Takehara K, et al. Clinical features of dermatomyositis associated with anti-MDA-5 antibodies by age. Modern Rheumatology. 2020;31(1): 177–185. doi:10.1080/14397595.2020.1740400.
- Sontheimer RD. MDA5 autoantibody — another indicator of clinical diversity in dermatomyositis. Annals of Translational Medicine. 2017;5(7): 160.
- Yashiro M, Asano T, Sato S, Kobayashi H, Watanabe H, Miyata M, et al. Anti- MDA5 antibody- positive hypomyopathic dermatomyositis complicated with pneumomediastinum. Fukushima Journal of Medical Science. 2018;64(2): 89–94.
- Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest. 2009;136: 1341–1347.
- McPherson M, Economidou S, Liampas A, Zis P, Parperis K. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review. Seminars in Arthritis and Rheumatism. 2022;53: 151959.
- Romero-Bueno F, Diaz Del Campo P, Trallero-Araguás E, Ruiz-Rodríguez JC, Castellvi I, Rodriguez-Nieto MJ, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Seminars in Arthritis and Rheumatism. 2020;50(4): 776–790.
- So H, Wong VTL, Lao VWN, Pang HT, Yip RML. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis. Clinical Rheumatology. 2018;37(7): 1983–1989.
- Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2012;51(9): 1563–1570.
- Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti- melanoma differentiation- associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology Oxford). 2010;49(9): 1713–1719.
- Huang K, Vinik O, Shojania K, Yeung J, Shupak R, Nimmo M, et al. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review. Rheumatology International. 2019;39(11): 1971–1981. doi:10.1007/s00296-019-04398-2.
- Labrador-Horrillo M, Martinez MA, Selva-O’Callaghan A, Trallero-Araguas E, Balada E, Vilardell-Tarres M, et al. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. Journal of Immunology Research. 2014;2014: 290797.